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Abstract
Crocus sativus and its bioactive constituent crocin are well known for anti-tumor potential in different models.
However, the efﬁcacy of crocin on in-vivo melanoma metastasis is not yet reported. In this study, melanoma
metastatic model was developed by tail vein injection of B16F-10 cells in to C57BL/6 mice. Metastatic mice treated
with two different doses of crocin (250 and 500 µg/kg of bodyweight) for 10 days and parameters such as lung
metastasis inhibition, mean survival time, lung hydroxyproline, uronic acid and hexosamine levels were analyzed
after 21 days of treatment. Then blood was collected and serum gamma glutamyl transpeptidase (g-GGT), sialic acid,
tumor necrosis factor alpha (TNF-α), interleukin 10 (IL-10), IL-6, IL-2, and TIMP-1 levels were measured. Further, a
lung histological examination was done in crocin treated metastatic mice. Subsequently hallmark metastatic
parameters such as matrix metalloproteinases (MMPs), extracellular regulated kinase 2 (ERK2), vascular endothelial
growth factor (VEGF), and K-ras gene expression were investigated in the lungs of crocin treated metastatic mice.
Further, in-vitro adhesion, invasion and migration of B16F-10 cells were examined after 24 hours of crocin (5 and 10
µg/mL) treatment. Administration of crocin to tumor bearing C57BL/6 mice reduced the lung metastasis by 85%.
Elevated levels of hydroxyproline, uronic acid, hexosamine, serum sialic acid and g-GGT in metastatic control were
found to be signiﬁcantly reduced in crocin treated mice. Crocin also inhibited expression of MMP-2, MMP-9, ERK-2,
K-ras, and VEGF. Crocin reduced the ability of B16F-10 cells invasion (P< 0.05), migration (P< 0.05) and adhesion
by upregulating E-cadherin expression. In conclusion, crocin elicited marked anti-metastatic potential by regulating
the metastasis induced biomarkers.
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Introduction
Malignant melanoma is a potentially fatal form of
skin cancer, with a strong capacity for invasion and
metastasis, and high rates of recurrence and mortal-
ity[1–2]. The median survival following the onset of
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distant melanoma metastasis is just 6-9 months and the
ﬁve year survival rate is < 5%[3]. Melanoma progression
and metastasis is necessarily a complex multistep
process, as a cancer cell must acquire the ability to
survive under anchorage independent conditions,
invade through the surrounding stroma and migrate,
intravasate into the vascular system; extravasate and
subsequently endure a disadvantageous distant environ-
ment, adhere to the local tissue, and proliferate[4].
Matrix metalloproteinases (MMPs), which are the
most important factor secreted by tumor cells, stromal
ﬁbroblasts, or inﬁltrating inﬂammatory cells in the
tumor microenvironment, have been strongly impli-
cated in multiple stages of invasive and metastatic
progression of tumor cells. Furthermore, MMP-9 is
important for tumor angiogenesis by enhancing the
availability of vascular endothelial cell growth factor
(VEGF) in malignant tumors[5]. The interaction of
VEGF with its cognate receptor VEGFR on the surface
of endothelial cells promotes the recruitment and
proliferation of endothelial cells via the activation of
PI3K/Akt and Ras/Raf/MEK/ERK signaling[6]. In the
majority of cancer patients, by the time of diagnosis of
the primary tumor, metastasis to the regional lymph
node and/or distant organs has occurred[7]. For patients
with metastatic melanoma, the current therapy is based
on the use of the alkylating agent dacarbazine, and some
patients also receive interleukin (IL) - 2 systemically[8].
However, 90% of cancer deaths are caused by
metastasis that are resistant to conventional therapies
such as radiation and chemotherapy[9]. There are several
drugs that are available for cancer therapy; however, not
a single drug emerged as a promising agent to halt these
multiple steps of melanoma metastasis.
Plants have a long history of use in the treatment of
cancer[10]. Almost 60% of drugs approved for cancer
treatment are of natural origin[11]. Many experimental
studies and clinical trials showed that many natural
plants played an important role in blocking lung
metastasis from primary tumors[12–14]. Many herbal
drugs such as alcoholic extract of Thuja occidentalis[15],
aqueous-methanol (3:7) extract of Boerhaavia dif-
fusa[13], methanolic extract of Withania somnifera
roots[12], naturally occurring allyl and phenyl isothio-
cyanates[16], curcumin[17], and sulphorafane[14], etc.
have been reported to inhibit melanoma metastasis.
In this study we tried to explore anti-metastatic
potential of Crocus sativus L in a melanoma model. C.
sativus commonly known as saffron which is a dietary
herb of the Iridaceae family. Principal components of
saffron are safranal, crocin, picrocrocin and crocetin and
they are pharmacologically active[18]. Anti-cancer and
anti-tumor properties of saffron have been studied in
several cancer cell lines and animal models[19]. It is well
reported that saffron can induce apoptosis in different
cancer cell lines[20–21]. Our previous studies show that
saffron can inhibit the growth of different cancer cells
such as breast[22], pancreatic[23], and lung[22]; and it is
also shown to be an active tumor remission agent in
Dalton's lymphoma model[24]. Extract of Italian C.
sativus has been shown to be an anti-proliferative agent
in B16-F10 melanoma cell line[25]. Crocin is a major
active component of saffron as reported by our group
and elsewhere. Crocin possesses signiﬁcant anti-
proliferation effects on human colorectal cancer
cells[26]. This carotenoid can induce signiﬁcant altera-
tion of gene expression proﬁle of T24 (transitional cell
carcinoma of bladder) cells. Anti-tumor effects of crocin
are medicated at least in part by regulating the cell cycle
controlling gene expression[27]. However, efﬁcacy of
crocin on in-vivo melanoma metastasis and its prog-
nostic biomarkers is not yet reported. To address this
issue, in this study we delineate the role of crocin on in-
vivo melanoma lung metastasis.
Materials and methods
Plant material and extraction
Saffron stigma was powdered using mortar and
pestle. Powdered materials were extracted with ethanol
and it is stored in -20°C until use. Active components
were identiﬁed by HPLC.
Isolation and characterization of crocin from
C. sativus
Crocin was isolated from saffron as previously
described[28]. Brieﬂy, 500 mg saffron was washed
thrice with 20 mL ethyl ether, and the residual ether was
evaporated in air. It was then suspended in 15 mL of
30% methanol (v/v) in distilled water and stirred for 5
minutes at room temperature. The extract was ﬁltered
through a 0.45 mm Millipore ﬁlter. It was then diluted
with 10 mmol/L phosphate buffered saline (PBS, pH =
7.4), and the concentration of crocin was adjusted to 25
mmol/L, using the coefﬁcient €443 = 89,000 M–1 cm–1
reported for crocin in aqueous solution[29]. The crocin
structure was elucidated on the basis of 1HNMR,
13CNMR, IR, and mass spectral data.
In-vitro anti-metastatic studies
Cell lines and culture method
B16F-10 (CRL-6475) melanoma cells were pur-
chased from ATCC, USA. Cells were cultured in
Dulbecco's modiﬁed eagle's medium (DMEM) with
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10% FBS and 1% antibiotics (penicillin/streptomycin)
and maintained in humidiﬁed cell incubator at 37°C and
5% CO2.
Tumor cell adhesion assay
Tumor cell adhesion assay was carried out as
described earlier[30]. Brieﬂy, B16F-10 cells were seeded
on to type I collagen coated wells of ﬂat-bottomed titer
plates, in the absence and presence of crocin (5 mg/mL,
10 mg/mL) and incubated at 37°C for 24 hours. After
incubation, cells were washed with PBS and adherent
cells were ﬁxed, stained with Giemsa staining and
counted under a microscope. Data were presented as
meanSD of triplicates of three independent experi-
ments.
Collagen matrix invasion assay
Tumor cell invasion assay was carried out in modiﬁed
Boyden Chamber as described earlier[31]. Brieﬂy, the
lower compartment of the chamber was ﬁlled with
serum free DMEM and polycarbonate ﬁlter of 8 mm
pore size was placed above this. Each ﬁlter was coated
with 25 mL of type I collagen to form a thin continuous
ﬁlm on the top of the ﬁlter. B16F-10 melanoma cells
(105/150 mL DMEM) were added to the upper chamber
and incubated at 37°C in 5% CO2 for 24 hours in the
presence and absence of different concentrations of
crocin (5 mg/mL, 10 mg/mL). After 24 hours of
incubation, the cells on the lower surface of the
membrane ﬁlter were ﬁxed, stained and counted. Data
were presented as percentage of invasion of triplicates
of three independent experiments.
Tumor cell migration assay
Tumor cell migration assay was performed similar to
invasion assay except that polycarbonate ﬁlters were
collagen free. Crocin (5 mg/mL, 10 mg/mL) was added
along with B16F-10 melanoma cells to the upper
compartment of the Boyden chamber. After incubation
at 37°C for 24 hours, the number of cells migrating to
the lower chamber was determined using a haemocyt-
ometer. The results are expressed as percentage motility
of triplicates of three independent experiments.
Determination of the effect of dietary crocin on expression
of E-cadherin expression
The whole cell lysate was prepared from crocin (10
µg/mL) treated B16F-10 melanoma cells after 24 hours
as described earlier[32]. Then whole cell lysate were
resolved in a 10% SDS polyacrylamide gel electro-
phoretically and electro transferred onto a nitrocellulose
membrane. The immunoblots was probed with anti-E-
cadherin antibody and visualized with the NBT/BCIP
chromogenic substrate and documented.
In-vivo anti-metastatic studies
Animals
Six to eight week old male C57BL/6 mice were used
for the study. Mice were maintained under standardized,
environmental conditions (22-28°C, 60%-70% relative
humidity, 12 hours dark/light cycle and water ad
libitum). All the experiments were conducted under
the guidelines of Institutional Animal Ethical Commit-
tee.
Induction of metastasis
Metastasis was induced to animals by injecting B16F-
10 melanoma cells (1106 cells/animal) via the lateral
tail vein[33].
Drug preparation
Crocin was dissolved in minimum volume of ethanol
and re-suspended in 1% gum acacia and was given to
animals intraperitoneally (i.p) at a concentration of 250
µg and 500 mg/kg body weight.
Determination of in-vivo anti-metastatic potential of
crocin
After induction of metastasis, the mice were divided
in to four groups (n = 12). Group I animals were kept as
normal control and group II as metastatic tumor bearing
control receive saline intraperitoneally. Group III and IV
received 250 µg and 500 mg/kg body weight, respec-
tively, of crocin intraperitoneally for 10 days consecu-
tively from the day of tumor induction. After the
treatment period, six animals from each group were
sacriﬁced and then blood was collected by heart
puncture and the serum was separated. Further, lungs
were excised and thoroughly washed in PBS and
peripheral lung nodules were counted and used to
estimate various biochemical parameters such as
hydroxyproline, hexosamine, and uronic acid. Serum
g-glutamyl transpeptidase (g-GT) and sialic acid were
estimated by ELISA. The remaining six animals in all of
the groups were observed for survival. Histopathologi-
cal analysis was carried out by ﬁxing both whole lungs,
treated and untreated control animals in formaldehyde
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(10%) and then dehydrated using gradient alcohol and
embedded in parafﬁn wax. Sections (4 mm) were stained
with hematoxylin and eosin.
Determination of the effect of dietary crocin on cytokine
and TIMP-1 production in metastatic tumor bearing
animals
Metastasis was induced in 4 groups of C57BL/6 mice
(n = 12). Group I was normal control and Group II was
metastatic control. Group II and III animals had
received crocin at 250 µg and 500 mg/kg body weight,
respectively, continuously for ten days. Six animals
from each group were sacriﬁced on day 7 and 21 after
treatment. Then serum cytokines such as IL-10, IL-6,
TNF-α, IL-2 and TIMP-1 were measured using
respective ELISA kits by following the manufacturer's
instruction.
Gene expression proﬁle of MMP-2, MMP-9, ERK-2,
VEGF, and K-ras
The animals were sacriﬁced on day 21 after
treatment. Then lungs were excised and RNA was
extracted using guanidium thiocynate and cDNA was
synthesized as described elsewhere. PCR was per-
formed using speciﬁc primers of MMP-2, MMP-9,
VEGF, Erk-2, and K-ras. PCR products were resolved
by agarose gel electrophoresis and visualized using
ethidium bromide dye.
Statistical evaluation
In-vitro data presented as meanSD of triplicates of
three independent experiments. In-vivo data were
presented as meanSD of two triplicates. Experimental
data was evaluated by Students' t-test and Graph PAD In
stat software, Kyplot. Signiﬁcant differences between
each set of data were considered at the conﬁdence level
of P< 0.05 and P< 0.001.
Results
Inhibition of lung metastasis by crocin
A signiﬁcant reduction in the number of pulmonary
metastatic colonies of B16F-10 melanoma cells were
observed in crocin treated mice compared to metastatic
tumor bearing control. Administration of crocin 250 and
500 µg/kg of bodyweight reduced percent of lung
metastasis by 80% and 85% respectively in a dose
dependent manner (P < 0.001) (Fig. 1A). Further
morphology and histopathological data clearly showed
signiﬁcant reduction of lung metastasis in crocin treated
mice compared to untreated metastatic control (Fig. 1B,
C). These data strongly support the anti-metastatic
activity of dietary crocin.
Mean survival time and body weight of crocin
treated mice
Mean survival time of crocin (250 and 500 µg/kg of
body weight) treated mice was extended up to 27.1 and
31 days respectively compared to untreated metastasis
control mice where the survival ended after 26 days of
the experimental period (Fig. 2A). Furthermore, body
weight was measured in normal mice fed with crocin
(250 and 500 µg/kg of body weight) for four weeks. We
found no signiﬁcant difference in bodyweight of crocin
treated mice compared to control mice (Fig. 2B). This
data reveals that crocin can be tolerated by mice without
eliciting toxicity.
Efﬁcacy of crocin on reduction of lung hydroxypro-
line, uronic acid and hexosamine content
Elevated levels of hydroxyproline (22.170.93 mg/
mg of tissue dry weight), uronic acid (360.5813.04
mg/100 mg tissue dry weight), and hexosamine
(4.360.63 mg/100 mg tissue dry weight) was observed
in metastatic control mice. Moreover, 250 and 500 mg/
kg of body weight crocin treatment reduced their levels
signiﬁcantly and brought back near to normal control
(Fig. 3A, B, C).
Role of crocin on serum γ- GGT and sialic acid
As serum sialic acid and g-GGT are lung metastatic
biomarkers in this study, we measured their levels in
crocin treated metastatic mice. Both sialic acid
(21.781.98 mg/mL) and g-GGT (118.115.83 nmol
p-nitroaniline/mL) levels increased signiﬁcantly in
metastatic mice compared to normal control. Crocin
treatment reduced sialic acid and g-GGT levels
signiﬁcantly at the end of experimental period (Fig. 4
A, B).
In-vitro adhesion, invasion andmigration of B16F-10
cells upon crocin treatment
B16F-10 cells treated with crocin (5 and 10 µg/mL)
for 24 hours showed dose-dependent decline in
adhesion (85.5% and 73.5%, respectively), invasion
(57.2% and 29.2%, respectively), and migration
(76.03% and 55.87%, respectively) (Fig. 5A, B, C).
Further, high expression of E-cadherin was observed in
crocin (10 µg/mL) treated B16F-10 cells (Fig. 5D).
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Fig. 1 Effect of dietary crocin on lung metastasis. A: Effect of dietary crocin on remission of lung metastasis. B: Effect of dietary crocin on
number of lung metastatic nodules. C: Effect of dietary crocin on morphology of lungs of metastasis induced animals. Data are presented as
meanSD of two triplicates. ** - indicates signiﬁcant difference at P< 0.001 compare to metastatic control. D. Effect of dietary crocin on
histopathological analysis of lungs of metastasis bearing animals. The lungs were dissected out and observed for metastasis (tumor nodules) on
day 22 after tumor challenge. For histopathological analysis, the peripheral lung nodule tissue was ﬁxed in 10% buffered formalin and sectioned
of 4 μm thickness and embedded in parafﬁn. Then tissue sections were stained with hematoxylin-eosin and the number and area of metastatic
nodules (% tumor area of the whole lung) were measured as described earlier. Scale bar indicates 10 μm.
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Activation of TIMP1 and deactivation of MMP (2
and 9), VEGF, ERK2, and K-ras by crocin
As MMP2 and MMP9 facilitates the detachment of
tumor cells from primary tumor site and VEGF
promotes dissemination via ERK2 and Ras, TIMP1
is directly involved in inhibition of MMP's and
halt metastatic process. To determine the role of crocin
on these signaling molecules in this study, we measured
the serum TIMP1 level and expression of MMP's,
ERK2 and Ras in crocin treated mice. Serum TIMP-1
level in untreated metastatic tumor bearing control
mice was 553.9621.41 pg/mL and increased with
treatment of crocin after 7 days (250 µg/ kg of
body weight (591.7171.33 pg/mL), 500 µg/ kg of
body weight (640.2024.09 pg/mL) and 21 days
(250 µg/ kg of body weight (654.2923.67 pg/mL),
500 µg/ kg of body weight (693.835.8 pg/mL)
(Fig. 6A). Further expression of MMP-2, MMP-9,
VEGF, Erk-2 and Ras (Fig. 6B) were considerably
reduced by crocin treatment in comparison to metastatic
control.
Efﬁcacy of dietary crocin on serum TNF-α, IL-6, IL-
2, and IL-10
TNF-α (day 7: 262.128.42 pg/mL; day 21:
630.809.54 pg/mL) and IL-6 (day 7: 335.083.65
pg/mL; day 21: 580.2816.6 pg/mL) were signiﬁcantly
elevated in metastatic mice compared to normal control.
Administration of crocin at 250 and 500 µg/kg of body
weight reduced TNF-α (day 7: 153.35.53 pg/mL and
145.455.3 pg/mL, respectively; day 21: 74.783.42
pg/mL and 65.432.33 pg/mL, respectively), IL-6 (day
Fig. 2 Effect of dietary crocin on mean survival time and body
weight. A: Effect of dietary crocin on mean survival time in tumor
bearing animals. Data are presented as meanSD (n = 12). B: Effect
of dietary crocin on body weight of mice. Normal mice were fed with
different doses of crocin (250 and 500 μg/kg of body weight) and
body weight was observed for four weeks on weekly intervals. Data
are presented as meanSD (n = 5).
Fig. 3 Effect of dietary crocin on the lung biochemical
parameters. A: Hydroxyproline content. B: Uronic acid content.
C: Hexosamine content. Data are presented as meanSD of two
triplicates. *and** - indicates signiﬁcant difference at P< 0.05 and
P< 0.001, respectively, compared to metastatic control.
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7: 72.071.66 pg/mL and 68.773.77 pg/mL,
respectively; day 21: 257.434.39 pg/mL and
235.8912.2 pg/mL, respectively) levels signiﬁcantly
(P< 0.001) (Fig. 7A, B). In contrast, IL-2 level was
reduced on day 7 (18.671.3 pg/mL) and slightly
elevated on day 21 (630.89.54 pg/mL) in metastatic
mice compared to control. Similarly, IL-10 level also
declined on day 7 (21.230.95 pg/mL) and enhanced
on day 21 (630.89.54 pg/mL) in metastatic mice
compare to normal control. Treatment with crocin at
250 and 500 µg/ kg of body weight enhanced IL-2
(day 7: 30.20.32 pg/mL and 35.462.65 pg/mL,
respectively; day 21: 48.711.26 pg/mL and
51.511.31 pg/mL respectively), IL-10 (day 7:
1082.51 pg/mL and 2975.27 pg/mL, respectively;
day 21: 2184.18 pg/mL and 3122.78 pg/mL,
respectively) levels signiﬁcantly (P < 0.001)
(Fig. 7C, D).
Fig. 4 Effect of dietary crocin on the serum γ-GT and sialic acid levels in metastasis bearing animals. A: Serum γ-GT. B: Serum sialic
acid. Data are presented as meanSD of two triplicates. *and** - indicates signiﬁcant difference at P < 0.05 and P< 0.001, respectively,
compared to metastatic control.
Fig. 5 Effect of dietary crocin on adhesion, invasion, migration and E-cadherin expression. B16F-10 melanoma cells were used. A: % of
adhesion. B: % of invasion. C: % of migration. D: E-cadherin expression. Data are presented as meanSD of triplicates of three independent
experiments. * and ** - indicates signiﬁcant difference at P< 0.05 and P< 0.001, respectively, compared to metastatic control.
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Discussion
Advanced metastatic melanoma is highly recalcitrant
to treatment due to massive spreading and its aggressive
nature. Targeted immunotherapy using a cocktail of
monoclonal antibodies elicits severe post treatment
allergic reactions. In this scenario, recent scientiﬁc
efforts have focused on the potential roles of traditional
herbs as an alternative and complementary medication
for cancer treatment. Extensive research on dietary
herbs over the past two decades found that some herbs
inhibit different types of tumor growth in-vivo and halt
in-vitro cancer cell proliferation. Many plant derived
bioactive constituents, including paclitaxel (from Taxus
Fig. 6 Effect of dietary crocin on the TIMP-1 level, MMP-2 and MMP-9, VEGF, ERK, and K-Ras expression in metastasis bearing
animals. A: TIMP1. * - indicates signiﬁcant difference at P< 0.05 compare to metastatic control. B: Expression of MMP-2, MMP-9, VEGF,
ERK, and K-Ras. Lane 1: Molecular weight marker; Lane 2: Untreated metastatic tumor bearing control; Lane 3: Treated with Crocin (250 μg/kg
body weight); Lane 4: Treated with Crocin (500 μg/kg body weight); Lane 5:GAPDH.
Fig. 7 Effect of dietary crocin on serum TNF-α, IL-6, IL-2 and IL-10 in in metastatic bearing animals. Data are presented as meanSD
of two triplicates. * and ** - indicates signiﬁcant difference at P< 0.05 and P< 0.001, respectively, compared to metastatic control.
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brevifolia), camptothecin (from Camptotheca acumi-
nata), podophyllotoxin (from Podophyllum emodi), and
vinblastine (from Catharanthus roseus), have been
developed as potential sources of anticancer agents[34].
Crocus sativus and its active constituent crocin is tumor
inhibitory agent in a variety of in-vivo tumor models[19].
Crocin is the major constituent of C. sativus shown to be
an effective anti-tumor agent[22–23]. However, efﬁcacy
of crocin on melanoma metastasis is not yet reported. It
is well known that B16F-10 melanoma cells are highly
metastatic and form tumor nodules in the parenchyma of
the lungs when administered through the tail vein[33].
Therefore, in this study, we tested the efﬁcacy of crocin
on metastatic melanoma model generated by tail vein
injection of B16-F10 cells.
Administration of crocin at 250 and 500 µg/ kg of
body weight showed signiﬁcant inhibition of lung
metastasis at about 80% and 85% respectively after 21
days of the experimental period (Fig. 1). Tumor nodules
are metastatic colonies of B16F-10 melanoma cells
formed in the lungs, and they initiate lung ﬁbrosis and
collagen deposition. Tumor nodule inhibition by drugs
correlated with an increase in the life span of the
metastatic tumor bearing animals. In our study, mean
survival of metastatic mice fed with crocin (500 µg/kg
of body weight) extended up to 31 days compare to
control (Fig. 2). As per the WHO, dietary herbs and
their constituents are highly tolerable by the human
system compared to synthetic products. Our previous
study showed that 300 mg/kg of body weight of C.
sativus extract administration to normal mice is safe and
there was no adverse histopathologic differences
observed in the major organs[35]. The extent of lung
ﬁbrosis during metastasis correlated with lung collagen
hydroxyproline content because during lung ﬁbrosis,
collagen is deposited massively in the alveolus of the
lungs. Fifteen to thirty percent of collagen is hydro-
xyproline[36], which results in the reduction of pulmon-
ary function. High content of uronic acid results in
accumulation of hydroxyproline in lung metastasis.
Tumor cells produce uronic acid as a result of oxidation
of aldoses of sugar derivatives and leads to the
formation of esteriﬁed form of glucuronic acid.
Conversion of prohydroxyproline to hydroxyproline
by prolyl hydroxylase facilitated by the presence of
glucuronic acid. In addition glucuronic acid also
activates the ﬁber formation during lung ﬁbrosis[34].
Followed by uronic acid, hexosamine is a signiﬁcant
sugar derivative present in the tumor cells. It has an
important role in the synthesis of n-acetylneuraminic
acid (sialic acid), which is a component of glycolipids
present on the surface of tumor cells, thus promoting
growth and dissemination[36]. In our study, the level of
these molecules was enhanced in the lung tissue of
metastatic control. On treatment with crocin, the level of
uronic acid, hydroxyproline, and hexosamines brought
back signiﬁcantly and this observation indicates
reduced metastatic burden (Fig. 3A, B, C). Above
mentioned biochemical parameters are interconnected
to each other to facilitate lung metastasis and it is
directly correlated with the degree of lung metastasis.
Overall, our data reveals that levels of hydroxyproline,
uronic acid and hexamine in the lungs of metastatic
mice treated with crocin (250 and 500 µg/kg of body
weight) directly correlated with our lung metastasis
remission data (Fig. 1A) where we did not observe
drastic differences between the doses. However, the
molecular mechanism responsible for lack of dose-
dependency is unclear.
Rapidly growing tumors need cysteine for intracel-
lular reduced glutathione (GSH) synthesis in order to
obtain energy and to sustain growth and subsequent
dissemination. g-glutamyl transpeptidase (GGT)
cleaves GSH releasing g-glutamyl amino acids and
cysteinylg lycine, which is further cleaved by mem-
brane-bound dipeptidases into cysteine and glycine[37].
Further free g-glutamyl-amino acids, cysteine, and
glycine entering the cell serve as GSH precursors[38].
Hence, GGT expression facilitates tumor burden and
metastatic growth. In our study, we found that serum
GGT levels were enhanced in metastatic control but
crocin treatment reduced its level signiﬁcantly (Fig. 4A)
and it is evidenced from histopathological studies where
the metastatic nodules have disappeared after crocin
treatment. Sialic acids that are aberrantly expressed on
cancer cells appear to facilitate several steps of the
metastatic cascade[39]. In the current study, we found
that elevated serum sialic acid level in metastatic
control. High sialic acid expression favors metastasis
by facilitating cancer cell detachment and protection
from detachment-induced apoptosis (anoikis), enhan-
cing migration and tissue invasion by increasing
integrin interactions with the ECM, enabling interac-
tions with endothelial cells to extravasate from the
blood stream and form metastases[40]. Therefore,
inhibiting sialic acid expression could be of crucial
importance to halt metastatic cascade and subsequent
colonization at distant organs. Our result shows that
crocin treatment reduces the level of serum sialic acid
signiﬁcantly at the end of the experimental period (Fig.
4B). Molecular mechanism of crocin on reducing sialic
acid expression in metastatic mice is unclear; however,
it could be due to inhibitory effect of crocin on the
metastasis initiation cascade such as adhesion, invasion
and migration. The invasion of tumor cells into adjacent
tissues, a crucial event in metastasis, involves cell–cell
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and cell–ECM interactions[41]. These interactions
involve a number of adhesive molecules on the cell
surface, which have been described in detail[42]. Drugs
that can inhibit the adhesion of the cells to the ECMmay
have anti-metastatic potential. To address this issue in
this study, we evaluated the potential of crocin on in-
vitro adhesion, invasion and migration of B16-F10
cells. We found that there was dose-dependent decline
in the adhesion of B16-F10 cells with collagen matrix,
invasion and migration after crocin treatment (Fig. 5A,
B, C). Loss of E-cadherin facilitates detachment and
migration of tumor cells[43]. In our study, crocin
treatment restores the expression of E-cadherin com-
pares to metastatic control (Fig. 5D).
Matrix metalloproteinases (MMPs), MMP2 and
MMP9 in particular, have been regarded as major
molecules that assist tumor cells by cleaving several
ECM components and it paves the way for detachment
and dissemination during metastasis[44]. Tissue inhibi-
tors of metalloproteinases (TIMPs) act as natural
inhibitors of MMPs by tightly binding the MMP in a
1:1 stoichiometric ratio and are associated with normal
and pathological ECM turnover[45]. TIMP inhibits
MMP activity, thereby suppressing tumor invasion
and metastasis. This phenomenon led us to determine
the efﬁcacy of crocin onMMP 2, 9 and TIMP1. Level of
TIMP1 reduced in metastatic control but crocin
treatment enhanced their levels after 7 and 21 days of
the experimental period (Fig. 6A). Furthermore, crocin
administration inhibited expression of MMP 2 and 9 in
lung tissue of treated mice (Fig. 6B). Our results are in
agreement with previous studies where enhanced TIMP
expression can decrease metastasis and inhibit angio-
genesis in experimental mouse model[46]. Angiogenesis
is the hallmark of metastasis and vascular endothelial
growth factor (VEGF) is highly expressed in aggressive
melanoma cell lines and that melanoma patients with
higher VEGF concentrations have a higher rate of
relapse[47]. VEGF is one of the external stimuli to
induce the expression of MMP's and it would facilitate
migration. Inhibition of tumor growth has been
achieved in different melanoma xenograft models
through the use of a number of anti-VEGF strategies[48].
As we observed crocin treatment inhibited expression of
MMP's, we speculate that crocin could be anti-VEGF
component. Our data shows that mice treated with 250
and 500 µg/ kg of body weight of crocin completely lost
the expression of VEGF compared to metastatic control
(Fig. 6B). However, the molecular mechanism of crocin
on VEGF remains unclear. Survival, proliferation and
invasive responses of tumor cells have been shown to be
mediated by VEGF through Erk (1/2) pathways[49].
Furthermore, the interaction of VEGF on its cognate
receptor VEGFR of endothelial cells requires functional
activation of ERK (1/2) pathway, which operates
downstream of Ras, is often upregulated in tumors
and represents an attractive target for anticancer
therapy[50]. To identify the role of crocin on Ras/ERK
signaling in melanoma lung metastasis in this study, we
determine the gene expression pattern of Ras/ERK in
crocin treated mice. Crocin (250 and 500 µg/kg of body
weight) fed mice was associated with inhibition of Ras
and dose dependent decline of ERK2 expression (Fig.
6B). Our data suggest that crocin inhibits angiogenesis
by suppressing VEGF via downregulating ERK2 and its
downstream Ras (Fig. 6B). Similarly, thujone, a
monoterpene that inhibits melanoma lung metastasis
by downregulating ERK (1/2) and its downstream
Ras[50].
Cytokines play a pivotal role in triggering metastasis.
TNF-α shown to be an important cytokine mediator of
cancer metastasis in murine models[51]. Ocvirk et al.
found that concentrations of TNF-α were signiﬁcantly
higher in metastatic melanoma patients[52] and Cubillos
et al. suggested that the reduction in the number of
metastasis may be related to the effect of blocking TNF
activity in melanoma cells[53]. Similarly, in our study,
we found that the serum TNF-α level increased
signiﬁcantly in metastatic control mice but crocin
treatment reduced its level after 7 and 21 days of the
experimental period (Fig. 7A). Furthermore, in this
study, we measured serum interleukin (IL) 2, 6, and 10
levels in metastatic and crocin treated mice. IL-6 is
secreted by malignant melanoma cells, and the serum
level is associated with advanced stages of the disease.
Noticeably, serum IL-6 level was found to be
signiﬁcantly high in advanced melanoma patients[54].
In our study, we found that crocin treatment signiﬁ-
cantly reduced serum IL-6 level compared to metastatic
control (Fig. 7B). This implies that immune modulating
ability of crocin in melanoma metastasis. IL-2 has been
used for more than two decades in the therapy of
metastatic melanoma which, in some of treated patients,
resulted in induction of long-lasting remission[55].
Forced expression of IL-10 in human melanoma cells
did not enhance tumor growth and metastatic potential
in nude mice, but rather signiﬁcantly inhibited their
tumorigenicity and metastatic capabilities[56]. In the
current study, both IL-2 and IL-10 levels were enhanced
signiﬁcantly by crocin treatment at the end of the
experimental period (Fig. 7C, D). IL-10 has been shown
to inhibit the production of IL-1, IL-6, IL-8, TNF-α[57]
and forced expression of IL-10 suppressed VEGF and
MMP-9, secreted by tumor-associated macrophages in
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melanoma model[56]. Our results are in agreement with
this report since crocin treatment elevated the levels of
IL-10 and IL-2.
In conclusion, our experimental data has clearly
demonstrated that dietary crocin strongly inhibits lung
metastasis of B16F-10 melanoma cells in-vivo. Further-
more, crocin suppresses in-vitro adhesion, invasion, and
migration by upregulating E-cadherin. However, exten-
sive preclinical study is required to transform dietary
crocin as a cancer therapeutic agent for melanoma
patients.
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